Press Release
<< Back
Salarius Pharmaceuticals Announces Acceptance of Abstract for 2020 ASCO Virtual Scientific Program
The poster, titled, “A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma,” will provide an overview of the ongoing open-label, non-randomized dose-escalation/dose-expansion Phase 1/2 clinical trial of seclidemstat in patients with relapsed or refractory Ewing sarcoma. The primary objective of the trial is to assess seclidemstat’s safety and tolerability while secondary objectives include pharmacokinetics, preliminary efficacy and exploratory pharmacodynamic markers.
“We are pleased to be given the opportunity to provide a clinical trials in progress abstract for our lead investigational candidate, seclidemstat, a reversible LSD1 inhibitor now being evaluated in a Phase 1/2 clinical trial in patients with relapsed or refractory Ewing sarcoma,” said
Details of the presentation are as follows:
Title: | A phase I/II clinical trial of the reversible LSD1 inhibitor, seclidemstat, in patients with relapsed/refractory Ewing sarcoma |
Abstract Number: | TPS11567 |
Poster Number: | 455 |
Session: | Sarcoma |
About Salarius Pharmaceuticals, Inc.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These forward-looking statements may be identified by terms such as “will,” “could,” “believe,” “plan,” “expect,” “target,” and similar terms or expressions or the negative thereof. Examples of such statements include, but are not limited to, statements related to the following: the implication of having achieved certain study milestones, including dose escalation and enrollment milestones; the anticipated progress of Salarius’ clinical programs for seclidemstat; the anticipate release of data from Salarius’ trials; the status (including with respect to patient enrollment), design, conduct, and objectives of Salarius’ two Phase 1/2 clinical trials for seclidemstat; and Salarius’ exploration of additional indications for seclidemstat to expand the drug’s market potential. Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements are subject to risks and uncertainties which could cause actual results and performance to differ materially from those discussed in the forward-looking statements. These risks and uncertainties include, but are not limited to, the following: the sufficiency of the company’s capital resources; the ability of, and need for, the company to raise additional capital to meet the company’s business operational needs and to achieve its business objectives and strategy; the company’s ability to project future capital needs and cash utilization and timing and accuracy thereof; future clinical trial results and impact of results on the company; that the results of studies and clinical trials may not be predictive of future clinical trial results; the sufficiency of Salarius’ intellectual property protection; risks related to the drug development and the regulatory approval process; the competitive landscape and other industry-related risks; market conditions and regulatory or contractual restrictions which may impact the ability of Salarius to sell stock to Aspire Capital; the possibility of unexpected expenses or other uses of Salarius’ cash resources; risks related to the COVID-19 outbreak; and other risks described in Salarius’ filings with the Securities and Exchange Commission, including those discussed in the company’s quarterly report on Form 10-Q for the quarter ended
Investor Relations
(212) 375-2664 / 2694
mmcenroe@tiberend.com
mmiller@tiberend.com
Media Relations
Senior Vice President
(212) 375-2686
jbennett@tiberend.com
Source: Salarius Pharmaceuticals, Inc.